The report was first published in, Times Now News
Israel claims big breakthrough – says it has developed antibody against Coronavirus!
The Israel Institute for Biological Research (IIBR) has developed an antibody or passive vaccine which can attack and neutralise the virus responsible for COVID-19 within the bodies of those infected.
Israeli Defense Minister Naftali Bennett has confirmed that the Israel Institute for Biological Research (IIBR) has developed an antibody or passive vaccine which can attack and neutralise the virus responsible for COVID-19 within the bodies of those infected. Last month, IIBR started testing its antibody-based vaccine prototype on rodents.
Terming the development a ‘major breakthrough’, the minister said that he was shown the ‘antibody that attacks the virus in a monoclonal way and can neutralise it within the bodies of those ill’, said a statement from his office as reported The Times of Israel.
“I am proud of the institute staff for this terrific breakthrough,” Bennett was quoted as saying in the statement. The statement from the Defense Minister’s office, however, did not specify whether trials were conducted on humans.
Meanwhile, Israel is planning to set up the country’s first vaccine production facility in the small southern town of Yeruham. According to a report in The Jerusalem Post, a spokesperson for the Yeruham local council revealed the plan, which is in partnership with the Israel Institute for Biological Research (IIBR) and an international pharmaceutical company.
The report stated that a model that would enable for the establishment of the facility was presented. As per the model, the facility in Yeruham will manufacture tens of millions of vaccine units, of various types, which will help ensure the country self-sufficiency even in times of pandemics.
The plan, if approved by the Israeli government, will allow the facility to be built even before the IIBR completes the full development and approval for its vaccine, the report said.
As per the deal, infrastructure and manpower would be provided by the Yeruham local council, while IIBR will provide the research aspect. However, the model still depends on an undecided third partner for international operations, marketing and distribution purposes, added the report.
Reportedly, talks with two of the world’s largest international pharmaceutical companies – one from India and the other from the United States – are ongoing.
The IIBR said it is working to patent its COVID-19 antibody and secure a contract for its commercial development.
 has developed an antibody which can attack the virus responsible for COVID-19 within the bodies of those infected.){kind=link}